About us
We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
revolutionizing precision medicine
Board of Directors
Allan May
Chairman - Life Science Angels
Harrold van Barlingen
Thuja Capital
Shaun Rodriguez
Casdin Capital
Mark Oldroyd
Independent Board Member
Paul van de Wiel
CEO InnoSIGN
Jeroen Siemes
Observer BOM
Benno Tieke
Observer PhilipsManagement Team
Paul van de Wiel
Chief Executive Officer
Sigi Neerken
Chief Business Officer
Eveline den Biezen
Chief Technology Officer